PMS-FLUPHENAZINE DECANOATE INJ (BP) 25MG/ML 25 MG
FLUPHENAZINE DECANOATE : 25 MG · DIN 02091275 · PHARMASCIENCE INC
Health Canada status: CANCELLED POST MARKET
What is PMS-FLUPHENAZINE DECANOATE INJ (BP) 25MG/ML?
PMS-FLUPHENAZINE DECANOATE INJ (BP) 25MG/ML 25 MG contains FLUPHENAZINE DECANOATE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02091275, held by PHARMASCIENCE INC, supplied as LIQUID for INTRAMUSCULAR ; SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 04-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-FLUPHENAZINE DECANOATE INJ (BP) 25MG/ML used for?
Management of manifestations of schizophrenia in adults. Not indicated for severely agitated patients, psychoneurotic patients, or geriatric patients with confusion/agitation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02091275 |
|---|---|
| Brand name | PMS-FLUPHENAZINE DECANOATE INJ (BP) 25MG/ML |
| Generic / active ingredient | FLUPHENAZINE DECANOATE : 25 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 25 MG |
| Dosage form | LIQUID |
| Route of administration | INTRAMUSCULAR ; SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | N05AB02 FLUPHENAZINE |
| AHFS class | 28:16.08.24 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 04-Jul-2025 |
| Original market date | 1994-12-31 00:00:00 |
How is it administered?
Administered by IM or SC injection. Onset 24-72h; effects significant within 48-96h. Average duration 3-4 weeks. Maintenance therapy requires careful supervision and individual titration.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text.
How is it supplied?
Not explicitly detailed in the provided text (mentions 25 mg/mL and 100 mg/mL strengths).
Contraindications
Hypersensitivity to phenothiazines; cerebral atherosclerosis; subcortical brain damage; renal insufficiency; pheochromocytoma; severe cardiovascular disorders; comatose states; severe CNS depression.
Warnings and precautions
Increased mortality in elderly with dementia; Neuroleptic Malignant Syndrome; Tardive Dyskinesia; QT prolongation; Venous thromboembolism; may impair mental/physical abilities for driving.
Is FLUPHENAZINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by AA PHARMA INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for PMS-FLUPHENAZINE DECANOATE INJ (BP) 25MG/ML
What can be used instead?
Other Canadian products sharing ATC code N05AB02 FLUPHENAZINE. 3 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| FLUPHENAZINE | 1 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00405345 |
| FLUPHENAZINE | 2 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00410632 |
| FLUPHENAZINE | 5 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00405361 |
| APO FLUPHENAZINE TAB 2.5MG | 2.5 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00405353 |
| APO-FLUPHENAZINE INJECTABLE | 25 MG | LIQUID | APOTEX INC | CANCELLED POST MARKET | DIN 02244166 |
| FLUPHENAZINE 1 TAB 1MG | 1 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00563846 |
| FLUPHENAZINE 2 TAB 2MG | 2 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00563838 |
| FLUPHENAZINE 5 TAB 5MG | 5 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00563803 |
| FLUPHENAZINE DECANOATE INJECTION B.P. | 100 MG | LIQUID | HOSPIRA HEALTHCARE ULC | CANCELLED PRE MARKET | DIN 02189097 |
| FLUPHENAZINE DECANOATE INJECTION B.P. | 25 MG | LIQUID | HOSPIRA HEALTHCARE ULC | CANCELLED PRE MARKET | DIN 02189089 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for PMS-FLUPHENAZINE DECANOATE INJ (BP) 25MG/ML
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.